U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2Br.Mn
Molecular Weight 214.746
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MANGANESE BROMIDE

SMILES

[Mn++].[Br-].[Br-]

InChI

InChIKey=RJYMRRJVDRJMJW-UHFFFAOYSA-L
InChI=1S/2BrH.Mn/h2*1H;/q;;+2/p-2

HIDE SMILES / InChI
Molecular Formula Mn
Molecular Weight 54.938
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula BrH
Molecular Weight 80.912
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260883.htm

Manganese citrate is generally recognized as safe direct food additive. Manganese citrate complex has being used in the determination of liver enzyme activities in the aging process and following treatment with aminoethylisothiuronium bromide hydrobromide (AET).

CNS Activity

Originator

Approval Year

1921
1467
Targets

Targets

Primary TargetPharmacologyConditionPotency
Activator
1430
Activator
1430
Activator
1430
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Approved
8429
Unknown

Approved Use

Manganese is used for prevention and treatment of manganese deficiency, a condition in which the body doesn’t have enough manganese.
Primary
Approved
8429
Unknown

Approved Use

Manganese is used for weak bones (osteoporosis).
Palliative
Approved
8429
Unknown

Approved Use

Early research suggests that taking manganese along with calcium helps improve symptoms of PMS, including pain, crying, loneliness, anxiety, restlessness, irritability, mood swings, depression, and tension.
Curative
Approved
8429
MANGANESE SULFATE

Approved Use

Manganese Sulfate Injection, USP is indicated for use as a supplement to intravenous solutions given for Total Parenteral Nutrition (TPN). Administration helps to maintain plasma levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Primary
Approved
8429
MANGANESE SULFATE

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Metabolism of l-Tyrosine to 4-Hydroxybenzaldehyde and 3-Bromo-4-Hydroxybenzaldehyde by Chloroplast-containing Fractions of Odonthalia floccosa (Esp.) Falk.
1979 Dec
Effect of fluoride on copper, manganese and zinc in bone and kidney.
1981 Mar
Effect of quantity and route of administration of manganese monoxide on feed intake and serum manganese in ruminants.
1985 Feb
Transformation of BALB/c-3T3 cells: IV. Rank-ordered potency of 24 chemical responses detected in a sensitive new assay procedure.
1993 Jul
Manganese: brain transport and emerging research needs.
2000 Jun
Differential ability of transition metals to induce pulmonary inflammation.
2001 Nov 15
Glutamate/aspartate transporter (GLAST), taurine transporter and metallothionein mRNA levels are differentially altered in astrocytes exposed to manganese chloride, manganese phosphate or manganese sulfate.
2002 Sep
Manganese distribution across the blood-brain barrier. I. Evidence for carrier-mediated influx of managanese citrate as well as manganese and manganese transferrin.
2003 Jan
Persistent alterations in biomarkers of oxidative stress resulting from combined in utero and neonatal manganese inhalation.
2005 May
Alterations of oxidative stress biomarkers due to in utero and neonatal exposures of airborne manganese.
2006 Summer
Effects of chronic manganese exposure on glutamatergic and GABAergic neurotransmitter markers in the nonhuman primate brain.
2009 Sep
Safety Assessment of Citric Acid, Inorganic Citrate Salts, and Alkyl Citrate Esters as Used in Cosmetics.
2014 May
Chronic exposure to manganese sulfate leads to adverse dose-dependent effects on the neurobehavioral ability of rats.
2016 Nov
Intramolecular Aminoalkoxylation of Unfunctionalized Olefins via Intramolecular Iodoamination and Aziridinium Ion Ring-Opening Sequence.
2017 Apr 7
Patents

Patents

04048185
23
05089050
24
05261953
23
05629274
23
05700944
23
06136455
24
06548713
23
07091342
25
07384965
26
07544707
26
07598266
24
07615520
24
08460631
23
20020169331
23
20050222440
23
20060205615
24
20060205744
23
20090196809
23
20110203659
23
6589693
23
6627256
23
7435361
26
7687047
23
CA2165259A1
23
CA2517370C
23
DE102016209961
23
EP1627663A3
23
JP 2001058829 A
23
US 3585022 A
23
US20150218342
23
US2825631
23
US2916504
23
US2952519
26

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Curator's Comment: In vitro cytotoxicity of manganese oxide (MnO) using live/dead cell assay, lactate dehydrogenase assay, and reactive oxygen species detection with variation of the concentration of nanoparticles (5-500 ug/ml), incubation time (18-96 h), and different human cell lines (lung adenocarcinoma, breast cancer cells, and glioblastoma cells) was studied. The cytotoxic effect was negligible for 18 h incubation even at highest concentration of 500 ug/ml MnO nanoparticle.
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:56:00 UTC 2023
Edited
by admin
on Fri Dec 15 18:56:00 UTC 2023
Record UNII
U70U4T7N6S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MANGANESE BROMIDE
MI   WHO-DD  
Systematic Name English
MANGANESE DIBROMIDE
Systematic Name English
MANGANOUS BROMIDE
Common Name English
MANGANESE(II) BROMIDE
Systematic Name English
MANGANESE BROMIDE [MI]
Common Name English
Manganese bromide [WHO-DD]
Common Name English
MANGANESE BROMIDE ANHYDROUS
Common Name English
Code System Code Type Description
SMS_ID
100000086160
Created by admin on Fri Dec 15 18:56:00 UTC 2023 , Edited by admin on Fri Dec 15 18:56:00 UTC 2023
PRIMARY
WIKIPEDIA
MANGANESE(II) BROMIDE
Created by admin on Fri Dec 15 18:56:00 UTC 2023 , Edited by admin on Fri Dec 15 18:56:00 UTC 2023
PRIMARY
DAILYMED
U70U4T7N6S
Created by admin on Fri Dec 15 18:56:00 UTC 2023 , Edited by admin on Fri Dec 15 18:56:00 UTC 2023
PRIMARY
EVMPD
SUB03074MIG
Created by admin on Fri Dec 15 18:56:00 UTC 2023 , Edited by admin on Fri Dec 15 18:56:00 UTC 2023
PRIMARY
EPA CompTox
DTXSID2065460
Created by admin on Fri Dec 15 18:56:00 UTC 2023 , Edited by admin on Fri Dec 15 18:56:00 UTC 2023
PRIMARY
PUBCHEM
83471
Created by admin on Fri Dec 15 18:56:00 UTC 2023 , Edited by admin on Fri Dec 15 18:56:00 UTC 2023
PRIMARY
MERCK INDEX
m7060
Created by admin on Fri Dec 15 18:56:00 UTC 2023 , Edited by admin on Fri Dec 15 18:56:00 UTC 2023
PRIMARY Merck Index
FDA UNII
U70U4T7N6S
Created by admin on Fri Dec 15 18:56:00 UTC 2023 , Edited by admin on Fri Dec 15 18:56:00 UTC 2023
PRIMARY
CAS
13446-03-2
Created by admin on Fri Dec 15 18:56:00 UTC 2023 , Edited by admin on Fri Dec 15 18:56:00 UTC 2023
PRIMARY
ECHA (EC/EINECS)
236-591-9
Created by admin on Fri Dec 15 18:56:00 UTC 2023 , Edited by admin on Fri Dec 15 18:56:00 UTC 2023
PRIMARY
Related Record Type Details
Structure of MANGANOUS CATION
PARENT -> SALT/SOLVATE
Structure of MANGANESE BROMIDE TETRAHYDRATE
SOLVATE->ANHYDROUS
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966